An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
VERDICT
The label
Markup
read at $84.08
Crinetics Pharmaceuticals, Inc. holds its Markup at $84.08.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-07
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 16 days
Price
$84.08
Valuation
N/A trailing · -20.65 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.09
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$84.08
N/A P/E · -20.65 fwd
Our fair value
$85.00
1% discount
Analyst target (avg)
$85.00
+1% to current
Target low $85.00Analyst target rangeTarget high $90.00
▲ current $84.08 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$84.08
you are here
Conservative
$85.00
+1%
Analyst avg
$85.00
+1%
Our fair value
$85.00
+1%
Analyst high
$90.00
+7%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our model and the Street both land near today's price — fairly valued, with no strong edge either way.
Revenue growth
2,336.30%
Profit margin
0.00%
Debt to equity
3.96
Analyst consensus
Hold · 10 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its interest-bearing securities. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 4.3% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashInterest-bearing cash and securities are 82.3% of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is 9.1% of assets, under the 49% limit.Pass
Revenue purity675.5% of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Biotech chasing rare hormone cures offers slim value
Picture a lab team racing to turn an experimental pill into the first easy treatment for certain rare hormone disorders. Crinetics is that lab, with revenue jumping thousands of percent as it edges closer to late-stage data. Yet the shares already trade at our calculated fair value, leaving almost no cushion, and the business still posts no profits and a sharply negative return on equity.
The forward multiple sits deep in loss territory while ten analysts cluster around a hold rating and an $85 target that matches the current price. Ethical screens clear the company, yet the combination of zero margins, unknown competitive edge and a clinical-stage pipeline means any real payoff remains years away and far from certain.
Risks centre on trial setbacks or regulatory delays that could erase years of spending in one go. The low margin of safety simply does not compensate for that binary outcome set. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in CRNX's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
CRNX trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 143.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it strong buy, with a mean price target of $83. Entered 2026-07-25 · Distribution
JOURNAL
The dated journal · newest first, never edited
2026-07-25Distribution$83.86+143.3%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 143.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it strong buy, with a mean price target of $83.
2026-07-18Distribution$34.47+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (14 analysts) rates it strong buy, with a mean price target of $83.
2026-07-03Distribution$34.47+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$34.47Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$36.55
-4.8%
·
$952
-4.8%
2 months
$39.44
-11.8%
·
$882
-11.8%
3 months
$36.51
-4.7%
·
$953
-4.7%
6 months
$49.31
-29.5%
·
$705
-29.5%
1 year
$33.08
+5.1%
·
$1,051
+5.1%
2 years
$45.01
-22.7%
·
$773
-22.7%
3 years
$21.67
+60.5%
·
$1,605
+60.5%
5 years
$16.98
+104.8%
·
$2,048
+104.8%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever CRNX does next, these words stay.
Crinetics Pharmaceuticals, Inc. · CRNX · Markup · $84.08
Recorded 2026-08-07 · before the outcome · scored mechanically
